CTLA4 and melanoma: Given that multiple targeted immune checkpoint blockade therapies, especially PD-1 [47, 48] and CTLA4 [49, 50], have shown significant efficacy in melanoma treatment, SERP1 expression levels in SKCM patients may also influence the efficacy of immunotherapy.